Ordering
Available Variants1 mg
CHA.18844-1mg
Price
€60.56
Available – Dispatch in 14 days
10 mg
CHA.18844-10mg
Price
€368.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mg | CHA.18844-1mg | €60.56 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.18844-10mg | €368.00 |
suitable for fluorescence, 98.0-102.0% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C27H29NO11 · HCl |
|---|---|
| CAS Number | 25316-40-9 |
| Molecular Weight | 579.98 |
| UNSPSC Code | 51281818 |
| NACRES | NA.76 |
| PubChem Substance ID | 57650234 |
| EC Number | 246-818-3 |
| Beilstein/REAXYS Number | 4229251 |
| MDL number | MFCD00077757 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Danger |
| hcodes | H302,H340,H350,H360FD |
| pcodes | P202 - P264 - P280 - P301 + P312 - P308 + P313 - P405 |
| Hazard Classifications | Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
Doxorubicin hydrochloride, with a chemical formula of C27H29NO11.HCl and a CAS number of 23214-92-8, is a chemotherapeutic agent that belongs to the anthracycline class of drugs. It is widely used in the treatment of various types of cancer, including breast cancer, ovarian cancer, and lymphomas. Doxorubicin hydrochloride works by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. This results in the induction of apoptosis, or programmed cell death, in rapidly dividing cancer cells. The hydrochloride salt form of doxorubicin is highly soluble in water, making it suitable for intravenous administration. As a result, doxorubicin hydrochloride has become a cornerstone in cancer chemotherapy, offering a effective treatment option for patients with certain types of cancer. Its efficacy and safety profile have been well-established in numerous clinical trials.
